Positive airway pressure therapy may delay cognitive decline in sleep apnea patients

· In these studies, 96% participants had OSA (n= 60,840) and n=5,826 had baseline cognitive impairment (mild cognitive impairment [MCI] or AD).

· Of all study participants, n=43,973 obtained PAP therapy, and n=16,397 were untreated or in a placebo group.

· Most studies reported a protective effect of PAP therapy on MCI and AD incidence, e.g., delayed age at MCI onset, reduced MCI or AD incidence, slower cognitive decline, or progression to AD.

"These findings suggest the role of OSA as a modifiable risk factor for cognitive decline. The burden of cognitive disorders on aging adults and their families calls for modifiable risk factors to reduce their impact among adults and their families."

"Future researcher that focuses on PAP interventions as a potential means to alleviate the incidence of cognitive disorders and cognitive decline is needed, particularly among ethnoracial minority groups who have been underrepresented and under-investigated in the extant literature," they concluded.

Reference:

Positive Airway Pressure and Cognitive Disorders in Adults With Obstructive Sleep Apnea: A Systematic Review of the Literature Monica Moon Shieu, Afsara Zaheed, Carol Shannon, Ronald David Chervin, Alan Conceicao, Henry Lauris Paulson, Tiffany Joy Braley, Galit Levi Dunietz Neurology May 2022, 10.1212/WNL.0000000000200383; DOI: 10.1212/WNL.0000000000200383